Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD
Navdeep Tangri, Steven J. Chadban, Claudia Cabrera, et al.
Advances in Therapy (2022) Vol. 40, Iss. 1, pp. 265-281
Open Access | Times Cited: 23

Showing 23 citing articles:

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
Vivekanand Jha, Saeed Alghamdi, Guisen Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4405-4420
Open Access | Times Cited: 91
Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study
Steven J. Chadban, Mustafa Arıcı, Albert Power, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102615-102615
Open Access | Times Cited: 13
Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study
Glenn M. Chertow, Ricardo Correa‐Rotter, Kai‐Uwe Eckardt, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102614-102614
Open Access | Times Cited: 12
Long-term health consequences and costs of changes in alcohol consumption in England during the COVID-19 pandemic
Joshua Card-Gowers, Sadie Boniface, Jamie Brown, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0314870-e0314870
Open Access | Times Cited: 1
Inside CKD: Cost-effectiveness of multinational screening for chronic kidney disease
Navdeep Tangri, Kook‐Hwan Oh, Jason Choo, et al.
Kidney International Reports (2025)
Open Access
Holistic Impact of CKD: A Clinical, Economic, and Environmental Analysis by IMPACT CKD
Naveen Rao, Francisco Brotons-Muntó, Ana Flávia Moura, et al.
Kidney International Reports (2025)
Open Access
IMPACT CKD: Holistic disease model projecting 10-year population burdens
Stephen Brown, Juan José García Sánchez, Hannah Guiang, et al.
Kidney International Reports (2024) Vol. 9, Iss. 11, pp. 3156-3166
Open Access | Times Cited: 2
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis
Phil McEwan, Marco Hafner, Vivekanand Jha, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1407-1416
Open Access | Times Cited: 4
Effect of exercise-based rehabilitation on functional capacity and renal function in type 2 diabetes mellitus with nephropathy: a randomized controlled trial
Megha Nataraj, G. Arun Maiya, Shankar Prasad Nagaraju, et al.
International Urology and Nephrology (2024) Vol. 56, Iss. 8, pp. 2671-2682
Open Access | Times Cited: 1
A Systematic Literature Review on the Use of Dried Biofluid Microsampling in Patients With Kidney Disease
Megan K. Lamond, Andrew J. Chetwynd, Alan D. Salama, et al.
Journal of Clinical Laboratory Analysis (2024) Vol. 38, Iss. 7
Open Access | Times Cited: 1
Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study
Joshua Card-Gowers, Lise Retat, Ada Kumar, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 4, pp. 913-926
Open Access | Times Cited: 1
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis
Raymond Chuen‐Chung Chang, Joanna Huang, James Willard Hurst, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 8, pp. 834-842
Closed Access | Times Cited: 1
Projecting the population level burden of CKD progression according to urine albumin-to-creatinine ratio categories
Luca De Nicola, Ricardo Correa-Rotter, Juan F. Navarro‐González, et al.
Kidney International Reports (2024) Vol. 9, Iss. 12, pp. 3464-3476
Open Access | Times Cited: 1
Inside CKD: a microsimulation modelling study projects the clinical and economic burden of chronic kidney disease in Hungary
Lilla Szabó, Luca Adél Halmai, Erzsébet Ladányi, et al.
Frontiers in Nephrology (2024) Vol. 4
Open Access | Times Cited: 1
Proyección de la carga clínica y económica de la enfermedad renal crónica entre 2022 y 2027 en España: resultados del proyecto Inside CKD
Juan F. Navarro‐González, Alberto Ortíz, Ana Cebrián Cuenca, et al.
Nefrología (2024) Vol. 44, Iss. 6, pp. 807-817
Open Access
Evaluación de eventos clínicos y costes asociados a la adición de dapagliflozina al tratamiento de la enfermedad renal crónica: análisis de compensación de costes
Juan F. Navarro‐González, Alberto Ortíz, Ana Cebrián Cuenca, et al.
Nefrología (2024) Vol. 44, Iss. 6, pp. 857-867
Open Access
Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population
Lise Retat, Dunming Xiao, Laura Webber, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3905-3921
Open Access
Development and validation of a chronic kidney disease progression model using patient-level simulations
Mafalda Ramos, Laetitia Gerlier, A. Uster, et al.
Renal Failure (2024) Vol. 46, Iss. 2
Open Access
Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model
Roberto Ravasio, Andrea Marcellusi, Luca De Nicola
Global & Regional Health Technology Assessment (2024) Vol. 11, Iss. 1, pp. 231-238
Open Access
Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: Results of the Inside CKD project
Juan F. Navarro‐González, Alberto Ortíz, Ana Cebrián Cuenca, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 6, pp. 807-817
Open Access
Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis
Juan F. Navarro‐González, Alberto Ortíz, Ana Cebrián Cuenca, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 6, pp. 857-867
Open Access
The Clinical and Economic Burden of Chronic Kidney Disease in Poland: Inside Patient-Level Microsimulation Modelling of CKD
Anna Masajtis‐Zagajewska, Ralf Kurek, Katarzyna Modrzyńska, et al.
Journal of Clinical Medicine (2024) Vol. 14, Iss. 1, pp. 54-54
Open Access
#4875 MANAGEMENT OF TUBULOINTERSTITIAL DISEASE IN PREGNANCY: TEN-YEARS EXPERIENCE OF A NEPHRO-OBSTETRIC CLINIC
Estela Nogueira, Nadiesda Peres, Iolanda Godinho, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. Supplement_1
Open Access
Page 1

Scroll to top